Drug intelligence / Profile preview

SD-B03

Development stage: Preclinical
Lead developer: Sinedore Medicine
Modality: Peptides

Overview

SD-B03 is a peptide-based therapeutic candidate developed by Sinedore Medicine for the treatment of obesity. It functions as a Glucagon-like peptide 1 receptor (GLP-1R) agonist. By activating GLP-1R, the drug mimics the physiological actions of the incretin hormone GLP-1, which regulates glucose metabolism and appetite. The activation of these receptors in the brain and gastrointestinal tract promotes satiety and slows gastric emptying, facilitating weight loss. As of the current pipeline information, SD-B03 is in the lead optimization and preclinical development phase.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on SD-B03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD-B03.

Explore the full profile